脂肪生成
内质网
内分泌学
肠促胰岛素
内科学
胰高血糖素样肽-1
脂质代谢
糖原
胰高血糖素
利拉鲁肽
胰岛素
碳水化合物代谢
化学
新陈代谢
生物
生物化学
医学
2型糖尿病
糖尿病
作者
J Fontana,Zuzana Červinková,Michal Anděl
出处
期刊:Vnitr̆ní lékar̆ství
日期:2013-07-01
卷期号:59 (7): 551-8
被引量:1
摘要
Effects of glucagonlike peptide 1 (GLP1) on liver cells are very intensively studied. In the metabolism of saccharides GLP1 stimulates synthesis of glycogen and reduces glucose production - thus acting like insulin. In the lipid metabolism it enhances fatty acid oxidation and lipid transport from hepatocytes while reducing de novo lipogenesis - effects more similar to glucagon action. Some studies suggest beneficial effects of GLP1 on oxidative stress, endoplasmic reticulum stress, production of inflammatory mediators and dysfunction of biliary secretion. Current results suggest that drugs affecting incretin system could be used in the treatment of certain liver diseases (e.g. NAFLD and NASH) in the future. In the following article we mention the known effects of GLP 1 on liver functions and liver metabolism and we point out its possible future therapeutic use in the treatment of liver diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI